<?xml version="1.0" encoding="UTF-8"?>
<p id="Par93">Hereditary angioedema is a rare disease that results in spontaneous, recurrent, and potentially life-threatening attacks of swelling in various parts of the body [
 <xref ref-type="bibr" rid="CR155">155</xref>]. The disease is commonly associated with deficiency or dysfunction of C1-esterase-inhibitor and with excessive bradykinin production caused by overactive plasma kallikrein [
 <xref ref-type="bibr" rid="CR156">156</xref>]. Lanadelumab (Takhzyro) is a fully human mAb derived from the Dyax phage library; it directly binds the active site of plasma kallikrein to inhibit bradykinin production. Lanadelumab was approved in 2018 in the USA and Canada for prophylaxis against attacks of hereditary angioedema in patients aged ≥ 12 years [
 <xref ref-type="bibr" rid="CR157">157</xref>].
</p>
